secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kodiak Sciences Inc. (KOD)
CIK:        0001468748
Form:       8-K
Filed at:   2024-08-14T23:59:59+00:00
Accession:  0000950170-24-096985
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kodiak Sciences Q2 net loss $45.1M, cash $219.2M; three Phase  trials enrolling
-------------------------------------------------------------------------------

- Net loss $45.1M ($0.86/sh) vs $80.2M ($1.53/sh) in Q2 2023; R&D expense down 52% to $32.5M.
- Cash and cash equivalents $219.2M; company believes funds operations into 2026.
- Phase 3 GLOW2 (diabetic retinopathy) and DAYBREAK (wet AMD) actively enrolling; Phase 1b APEX (KSI-101) enrolling.
- Appointed Dolly Chang (ex-Genentech) as CSO; promoted Almas Qudrat (CQO), Wayne To (CTO), Pablo Velazquez-Martin (CMO).
- Investor Day scheduled for September 23, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1468748/000095017024096985/0000950170-24-096985-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1468748/000095017024096985/kod-20240814.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-096985

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer